Asia-Pacific Acute Myeloid Leukemia Treatment Market Size

Statistics for the 2023 & 2024 Asia-Pacific Acute Myeloid Leukemia Treatment market size, created by Mordor Intelligence™ Industry Reports. Asia-Pacific Acute Myeloid Leukemia Treatment size report includes a market forecast to 2029 and historical overview. Get a sample of this industry size analysis as a free report PDF download.

Market Size of Asia-Pacific Acute Myeloid Leukemia Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Asia Pacific Acute Myeloid Leukemia Treatment Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 338.96 Million
Market Size (2029) USD 517.24 Million
CAGR (2024 - 2029) 6.46 %

Major Players

Asia Pacific Acute Myeloid Leukemia Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Asia-Pacific Acute Myeloid Leukemia Treatment Market Analysis

The Asia-Pacific Acute Myeloid Leukemia Treatment Market size is estimated at USD 338.96 million in 2024, and is expected to reach USD 517.24 million by 2029, growing at a CAGR of 6.46% during the forecast period (2024-2029).

Factors such as the high incidence and prevalence of acute myeloid leukemia and advancement in pharmacology and molecular biology to promote drug development in the Asia Pacific region are also anticipated to drive market growth over the forecast period. For instance, according to 'Leukaemia in Australia Statistics 2022', it was estimated that 5,202 new cases of leukemia were likely to be diagnosed in Australia (3,198 males and 2,004 females) in 2022. It was also estimated that a person had a 1 in 58 (or 1.7%) risk of being diagnosed with leukemia by the age of 85 (1 in 47 or 2.1% for males and 1 in 77 or 1.3% for females). Furthermore, government initiatives and funding for AML in the Asia Pacific region are likely to boost market growth.

According to a 2022 update from the Department of Health and Aged Care, from 1st March 2022, Australians with acute myeloid leukemia (AML) were likely to have access to a new treatment option through the Pharmaceutical Benefits Scheme (PBS). Mylotarg (gemtuzumab ozogamicin) was listed for the first time for the treatment of patients with previously untreated de novo CD33-positive AML, for use in combination with standard intensive chemotherapy.

The market is also expected to benefit from continuous developments in pharmacology and molecular biology for the creation of innovative medicines. Pharmaceutical companies competing in the market are investing a lot of money in research programs to develop new solutions. These R&D initiatives are also blamed for the shortcomings of the acute myeloid leukemia medicines now on the market. For instance, in August 2022, Daiichi Sankyo submitted a supplemental New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as continuation monotherapy for the treatment of adult patients in Japan with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

Thus, the high burden of acute myeloid leukemia advancement in pharmacology and molecular biology and strategic activities by the market players is expected to contribute to the market growth over the forecast period.

APAC Acute Myeloid Leukemia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)